AzTrials
AzTrials

Portal HypertensionNCT03451149

Feasibility And Safety Of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation Using A Radiofrequency Guidewire

A study testing Radiofrequency wire (Powerwire) in people with Portal Hypertension, run by Oregon Health and Science University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A novel radiofrequency (RF) wire created by Baylis Medical (Montreal, CAN) is an FDA cleared device commonly used for percutaneous recanalization procedures. This wire has an active tip that delivers focused RF energy and has been applied for many procedures such as percutaneous transseptal left heart access… Read more about this study

Who is it for?
Ages 20 to 99 years
Conditions the study is for
Portal Hypertension
What is being tested?
Radiofrequency wire (Powerwire)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
25 Oct 2017to 29 Jan 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with cirrhosis and portal hypertension meeting at least one indication for elective TIPS creation including refractory ascites, acute variceal bleeding not responsive to endoscopic treatment, prevention of recurrent variceal bleeding, portal hypertensive gastropathy, hepatorenal syndrome, Budd-Chiari syndrome, hepatic hydrothorax, hepatic veno-occlusive disease, and hepatopulmonary syndrome.
  • Patients who agree to undergo TIPS procedure and participate in this clinical study.
  • Age over 20 years

Who cannot join

  • Patients with a contraindication for TIPS including congestive heart failure, severe tricuspid regurgitation, severe pulmonary hypertension, uncontrolled systemic infection or sepsis and unrelieved biliary obstruction.
  • Patients in whom intravascular ultrasound cannot be used because of venous occlusion.
  • Decisionally impaired patients
  • Need for emergent TIPS creation

Trial locations and contacts

1 site in 1 country.

United States1 site
  • OHSU

    Portland, Oregon, 97239

Other trials in United States

About this study

Official title: Single-Arm, Single-Center, Pilot Study To Evaluate The Feasibility And Safety Of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation For Portal Hypertension Using A Radiofrequency Guidewire With Intravascular Ultrasound Guidance

A novel radiofrequency (RF) wire created by Baylis Medical (Montreal, CAN) is an FDA cleared device commonly used for percutaneous recanalization procedures. This wire has an active tip that delivers focused RF energy and has been applied for many procedures such as percutaneous transseptal left heart access, recanalization of central vein occlusion, recanalization of arterial occlusion, and recanalization of bile duct occlusion. There has been no study investigating the use of the RF wire for TIPS creation in clinical practice with humans. Having promising results of an experimental feasibility investigation in swine, the investigators are seeking to assess the feasibility and safety of the RF wire to cut through tissue in the liver while creating TIPS in the clinical setting.

Read the detailed description

The transjugular intrahepatic portosystemic shunt procedure (TIPS), first described in 1969 by Rösch et al., has been widely used to treat the complications of portal hypertension such as recurrent variceal hemorrhage and refractory ascites.

In the TIPS procedure, an intrahepatic connection between a hepatic vein and a portal vein branch is created in order to reduce the portal venous pressure. A dedicated device developed for the TIPS procedure, the Rösch-Uchida Transjugular Liver Access Set (RUPS), is widely used for this procedure. The most challenging and time-consuming part of TIPS creation is puncturing the portal vein from the hepatic vein with a long needle trocar. Occasionally in cirrhotic livers, the trocar needle can deflect and not easily pass through the parenchyma. Needle deflection may lead to additional needle passes and potentially increase risk of inadvertent injury to the liver or extracapsular puncture. There is need, therefore, for a device that can easily penetrate dense liver tissue without creating significant trauma.

A novel radiofrequency (RF) wire created by Baylis Medical (Montreal, CAN) is an FDA cleared device commonly used for percutaneous recanalization procedures. This wire has an active tip that delivers focused RF energy and has been applied for many procedures such as percutaneous transseptal left heart access, recanalization of central vein occlusion, recanalization of arterial occlusion, and recanalization of bile duct occlusion.

The investigators have assessed the application of the RF wire for TIPS creation in a swine model. The investigators found that the use of this wire to cut through tissue during TIPS creation is feasible in swine with some potential advantages compared with the current available tools. The RF wire device was well visualized under intravascular ultrasound (IVUS) guidance and could penetrate through the liver parenchyma smoothly and safely. In addition, the RF wire was able to subsequently be used as a working wire to complete the procedure. Advantages in clinical practice with cirrhotic livers would be the relative ease of penetration into a hardened liver compared to the trocar needle, and the additional benefit of being able to use the device as a working wire to minimize the risk of catheter displacement and decrease procedure time.

There has been no study investigating the use of the RF wire for TIPS creation in clinical practice with humans. Having the promising results of the experimental investigation in swine, the investigators are seeking to assess the feasibility and safety of the RF wire to cut through tissue in the liver while creating TIPS in the clinical setting. It is anticipated that the proposed experimental technique using the RF wire would be at least as safe as the current standard technique. The wire diameter, 0.035 inches, is smaller than the traditionally used 0.038 inch needle trocar, and the deposition of RF energy is limited to the wire tip with minimal collateral damage. Risks of complications, such as puncturing unintended structures including the liver capsule, hepatic artery, gallbladder and biliary tree are anticipated to be at least as low as for the standard technique, estimated at about 3-4%. Moreover, these risks may be reduced even further in the experimental technique owing to the use of intravascular ultrasound guidance, enabling direct visualization of the puncture compared to the standard technique using landmarks and reference images under x-ray fluoroscopy.

Being tested
Radiofrequency wire (Powerwire)
Keywords
TIPS
Medical subject headings
Hypertension, Portal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Radiofrequency wire (Powerwire)Device

    Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.

Study groups in NCT03451149
Study groupRoleWhat they receive
InterventionExperimentalUndergo transjugular intrahepatic portosystemic shunt creation using a radiofrequency wire (Powerwire) in lieu of a trocar needle to cut through liver parenchyma
Receives: Device: Radiofrequency wire (Powerwire)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility to use the device as anticipated

    Ability of the device to perform as anticipated

    Measured: within 24 hours

  2. Incidence of device-related adverse events (Safety)

    No device-related adverse events

    Measured: within 24 hours

Secondary outcomes (2)
  1. Penetrating ability

    To assess the capability of the RF wire to cut through tissue without significant deflection through parenchyma

    Measured: within 24 hours

  2. Device use as a standard working wire

    To assess the capability of the RF wire to act as the working wire for delivery of the TIPS set into the portal vein after access.

    Measured: within 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Mar 2018
  2. Study start25 Oct 2017
  3. Primary completion29 Jan 2019
  4. Study completion29 Jan 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Model description
A single group of up to 10 participants will be enrolled to evaluate a radiofrequency wire for cutting through liver parenchyma instead of the standard trocar needle during transjugular intrahepatic portosystemic shunt creation. This will be to test this device for feasibility and not health outcomes.
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03451149
Sponsor's protocol ID
OHSU eIRB # 16296
Status last verified
Nov 2023
First submitted
16 Feb 2018
Last updated
3 Nov 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: HIPAA compliant, IRB-approved, non-identifiable information may be provided for research outcomes purposes.

Questions about this trial

What is this clinical trial studying?

A study testing Radiofrequency wire (Powerwire) in people with Portal Hypertension, run by Oregon Health and Science University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility to use the device as anticipated (time frame: within 24 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in